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Abstract
Objective—Obesity is an important venous thrombosis (VT) risk factor but the reasons for this 
are unclear.
Materials and Methods—In a cohort of 20,914 individuals aged 45 and older without prior VT, 
we calculated the relative risk (RR) of VT over 12.6 years follow-up according to baseline body 
size measures, and studied whether associations were mediated by biomarkers of hemostasis and 
inflammation that are related to adiposity.
Results—Greater levels of all body size measures (weight, height, waist, hip circumference, calf 
circumference, body-mass index, waist-hip ratio, fat mass and fat-free mass) were associated with 
increased risk of VT, with 4th versus 1st quartile RRs of 1.5–3.0. There were no multiplicative 
interactions of biomarkers with obesity status. Adjustment for biomarkers associated with VT risk 
(factor VIII, von Willebrand factor, partial thromboplastin time, D-dimer and factor XI) only 
marginally lowered, or did not impact, the RRs associated with body size measures.
Conclusions—Greater body size, by multiple measures, is a risk factor for VT. Associations 
were not mediated by circulating levels of studied biomarkers suggesting that body size relates to 
VT because of physical factors associated with blood flow, not the hypercoagulability or 
inflammation associated with adiposity.
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Obesity is epidemic worldwide, with little evidence of improvement in recent years[1]. 
Other than age, obesity is the major atherosclerotic risk factor associated with risk of venous 
thrombosis (VT)[2–9]. In 2008 the United States Surgeon General called for more research 
on the reasons for an association of obesity with VT[10] yet few studies have 
comprehensively assessed obesity as a VT risk factor by including evaluation of many body 
size measures or by assessing mediating factors for associations of obesity with VT.
Mechanisms linking obesity to VT are speculative. The association may be due to physical 
factors related to obesity such as impaired venous return, biochemical effects of adipose 
tissue such as enhanced inflammation or hypercoagulability, or venous vessel wall 
alterations.
In the Longitudinal Investigation of Thromboembolism Etiology (LITE) we previously 
reported that obesity (BMI >30 kg/m2) was associated with a 2-fold higher risk of future 
VT[4]. With longer follow up and more than 200 additional VT events, we report here more 
detail on associations of body size measures, hemostasis and inflammation with VT. We 
hypothesized that several measures of body size are positively associated with VT risk and 
that the body fat component is more strongly related than non-fat mass. Under a hypothesis 
that adipose tissue directly influences the inflammatory and procoagulant state, we expected 
some degree of mediation of associations of body size by levels of hemostasis and 
inflammation markers.
Methods
Subjects
LITE is a prospective population-based study of 21,680 participants of the Cardiovascular 
Health Study (CHS) and the Atherosclerosis Risk in Communities (ARIC) study[11]. Both 
studies examined risk factors at baseline and followed participants for cardiovascular 
diseases. Detailed methods have been published[11]. In 1987–89, 15,792 men and women 
45–64 years of age were enrolled in ARIC; 27% were African American. In 1989–90, 5,201 
men and women age 65–100 were enrolled in CHS, and 687 African American participants 
were enrolled in 1992–93. Six communities are represented in LITE: Forsyth County, North 
Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; Washington County, 
Maryland; Sacramento County, California; and Pittsburgh, Pennsylvania. All participants 
provided written informed consent with methods approved by local institutional review 
committees.
At baseline, extensive information was collected using standardized methods, including 
medical history, medication use, measured height, weight, waist circumference, and hip 
circumference. BMI was calculated as weight in kg / height in m2, and waist-hip ratio was 
calculated. ARIC also measured calf circumference at the widest point of the right calf while 
the participant sat high enough that their feet did not touch the floor. CHS measured fat mass 
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and fat-free (lean) mass using bioelectric impedance with participants in the supine position 
wearing standard clothing[12]. Resistance was measured with a TVI-10 Body Composition 
Analyzer (Danninger Medican Technology Inc, Columbus, OH) at 50 kHz. Fat-free mass 
was estimated using the formula of Deurenberg: 6710*height2/(R + 3.1*S + 3.9), where R is 
resistance in ohms and S is sex (0 for women, 1 for men)[13]. Fat mass was calculated as the 
difference between weight and fat-free mass. Obesity status was categorized as normal, 
overweight, obese and severely obese by BMI <25, 25–30, 30–40, and 40+ kg/m2, 
respectively. The latter two categories were combined for some analyses. Elevated waist 
circumference was defined as ≥88 cm in women and ≥102 cm in men. Waist and hip 
circumferences, waist-hip ratio, fat and fat-free mass and calf circumference were also 
analyzed as continuous variables or in sex-specific quartiles of the distribution. Race was 
categorized as black and non-black. Diabetes was defined as fasting glucose ≥126 mg/dL, 
non-fasting glucose ≥200 mg/dL, use of diabetes medications or self-reported diabetes.
The two studies maintained longitudinal contact with participants to identify all 
hospitalizations. Potential cases of hospitalized VT were identified from ICD discharge 
codes and validated by medical record review by two physicians as previously reported[11]. 
VT events included deep vein thrombosis (DVT) and pulmonary embolism (PE). 
Classification as VT required positive imaging. VT cases ascertained in both cohorts with 
complete follow up through the end of 2001 (when CHS follow up for VT stopped) were 
included in this analysis. Cases were defined as provoked if they were associated with 
cancer, major trauma, surgery or marked immobility, and as unprovoked otherwise.
Laboratory Methods
For some hemostasis and inflammation factors, levels were measured in all participants of 
both cohorts. For others, a nested case-control study was used to randomly select two 
controls per case, frequency-matched to the cases by 5-year age group, sex, race (African-
American, white), follow-up time, and study (ARIC, CHS) [14].
In ARIC and CHS, fasting morning blood samples were obtained at baseline. Blood was 
centrifuged at 4°C, and plasma frozen at −70°C until analysis in central laboratories. 
Baseline levels of fibrinogen, factor VII and VIII coagulant activity (FVIIc, FVIIIc), and 
were measured, and in ARIC only, the activated partial thromboplastin time (aPTT), protein 
C and von Willebrand factor were measured, as previously described[15, 16]. Both studies 
measured white blood count at laboratories near each field center. In CHS only, baseline C-
reactive protein (CRP) and interleukin-6 (IL-6) were measured in the full cohort with high-
sensitivity assays[17]. In the nested case-control sample D-dimer was measured by 
immunoturbidometry using the Liatest D-dimer assay on the STAR analyzer (Diagnostica 
Stago) and factor XI by sandwich enzyme-linked immunoassay using reagents with affinity 
purified polyclonal antibodies from Enzyme Research Laboratories (South Bend, IN).
Statistical Methods
We excluded 729 participants reporting either prebaseline VT (n=590) or baseline warfarin 
use (n=185). Incidence rates were estimated as the number of VT events divided by the total 
number of person-years at risk. Some analyses only included one study (ARIC or CHS) if 
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variables of interest were only available in one study. Spearman correlation coefficients 
among study variables were calculated in the full cohort (or control group only for D-dimer 
and factor XI). In the full cohort, Cox regression models were used to estimate adjusted 
relative risks (hazard ratios) and 95% confidence intervals of VT associated with body size 
measures. In the nested case-control study, logistic regression was used to calculate odds 
ratios as estimates of relative risk. All models were adjusted for baseline age, sex and race. 
To assess whether biomarkers mediated the relationship of body size with VT we first ruled 
out presence of interactions between biomarkers and body size by using interaction terms in 
each model (all p interaction >0.05; supplementary table). We then used multivariable 
models adding the biomarkers and examined change in relative risk for the body size 
measure. Stratification was used for some analyses by whether the VT was provoked or 
unprovoked and by type of VT (DVT or PE+/−DVT). Differences in associations of body 
size measures by whether the outcome was DVT versus PE were assessed using the method 
of van Langervelde[18], concluding that associations were larger for PE than DVT if the 
RRPE/RRDVT was >2.0 and that they were larger for DVT than PE if this ratio was <1.0.
Results
With a median 12.6 years of follow up the incidence rate of first VT was 1.8 per 1,000 
person-years. Table 1 shows baseline characteristics of the 448 participants with first-time 
VT (269 in ARIC, 179 in CHS) and the 20,466 participants without VT. Older age and 
diabetes were more prevalent among cases and each body size measurement was larger 
among cases on average, except height, which was similar. Figure 1 shows the crude 
incidence rates for ARIC and CHS separately by categories of body size. There was a 
monotonically greater incidence of VT across BMI categories and quartiles of weight, waist 
circumference in ARIC, waist-hip ratio, and calf circumference (measured in ARIC only), 
but not height in either cohort and not waist circumference in the older CHS cohort, for 
which there was a J-shaped relationship. In the younger ARIC participants VT rates ranged 
from 0.7 to 1.0 per 1000 person years in the bottom category of each factor to 1.7 to 2.6 per 
1000 in the top category. Corresponding rates in the older CHS participants were 2.3 to 2.5 
per 1000, up to 3.3 to 6.2 per 1000. The inset in figure 1 shows that VT incidence rates in 
CHS also increased across categories of fat mass and fat-free mass, although for fat mass the 
rate was lower in the 3rd quartile than the 1st and 2nd.
Figure 2 shows associations of biomarkers with body size measures. The largest associations 
were direct associations of inflammation sensitive proteins with higher body size, and 
inverse associations of FXI with height and fat-free mass. The largest correlation was for 
CRP and fat mass in CHS participants, at 0.30. In CHS participants biomarkers tended to 
have direct associations with fat mass and inverse associations with fat free mass. D-dimer 
was weakly associated or unassociated with body size measures.
Table 2 shows the relative risk of VT for categories of each body size measure and 
biomarker combining CHS and ARIC since associations were similar by study (data not 
shown). All models were adjusted for age, sex and race. For all body size measures, there 
was a greater risk of VT across increasing categories of body size. The fourth versus first 
quartile adjusted relative risks ranged from 1.5 for height to 2.6 for weight. The adjusted 
Cushman et al. Page 4
Thromb Res. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
relative risk also increased across obesity status categories. For elevated versus normal waist 
circumference the relative risk was 1.7 (95% CI 1.4–2.1). Interpretations of the findings did 
not differ for any body size measure when analyses were limited to participants with 
complete biomarker data. Among the hemostasis and inflammation markers, higher levels of 
factors VII, VIII, XI, von Willebrand factor, D-dimer, CRP (marginally) and lower aPTT 
were associated with greater risk of VT, while the other factors were not.
There was no appreciable difference in the associations of body size measures with overall 
compared to unprovoked VTE (data not shown). As shown in table 3, RRs of body size 
measures were larger for events that were PE+/−DVT compared to DVT alone, although 
absolute risk differences were mostly similar across exposures. Severe obesity was the only 
body size category that conferred more than a 2-fold greater RR for PE+/−DVT than for 
DVT, suggesting this exposure is more strongly related to PE+/−DVT. These relative risk 
estimates were less precise for measures performed only in CHS or only in ARIC, but 
patterns were similar except for fat-free mass, which had a similar association with DVT and 
PE+/−DVT (data not shown).
We next evaluated whether adjustment for biomarkers related to VT risk mediated the 
association of body size measures with VT risk. Analyses assessed the relative risk of VT 
associated with a 1-SD increment of each body size measure (estimates shown in table 2). 
Including both ARIC and CHS, in models including age, sex and race, adjustment of body 
size measures for factor VII and factor VIII only trivially changed the relative risks of VT, 
with trivial defined as <0.1 unit change in relative risk. In the ARIC cohort addition of 
factors VII, VIII, aPTT and von Willebrand factor to the models resulted in a 0.1 unit 
attenuation of the relative risks per SD for weight, BMI, hip circumference and waist-hip 
ratio, and the other measures were trivially attenuated. In CHS, addition of factors VII, VIII 
and CRP to the models only trivially affected the relative risks. In the nested case-control 
study, addition of D-dimer and factor XI to the models also only trivially affected the 
relative risks. In sensitivity analyses, interpretation of results did not differ if only 
unprovoked cases were considered.
Discussion
The main findings of this study are that increased levels of several body size measures 
including height, weight, body-mass index, waist, hip and calf circumference were all 
associated with increased risk of future VT in the general population. Further, both fat mass 
and fat-free mass were risk factors. Associations were not substantially mediated by 
circulating levels of hemostasis and inflammation markers that relate to VT risk.
A few other studies assessed body size measures other than BMI in relation to VT risk. 
Hansson reported higher VT risk with increased waist circumference in men[19]. In the 
Nurses’ Health Study, BMI was more strongly related to risk of PE than waist-hip-ratio [7]. 
In the Tromso Study, height was a risk factor for VT in men but not women[20]. Conversely, 
height was positively associated with VT in a study of women,[21] was not associated with 
VT in a Dutch study[5], and was associated with fatal PE in a meta-analysis of cohort 
studies[22]. In a Danish cohort study, measured levels of weight, hip and waist 
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circumference, fat weight and BMI were positively associated with risk of VT[23]. We 
previously reported an association of higher waist circumference with VT in a study focused 
on metabolic syndrome and VT risk[24]. In the Tromso study, among different measures of 
body size, the top quintile of waist circumference showed the highest risk estimates for VT; 
HR 3.6 in men and 2.3 in women [25]. The highest RR in the current study was for BMI in 
the top quartile, RR 3.0.
Few studies have addressed whether biomarkers might mediate the association between 
obesity and VT risk, and results are inconsistent. In two case-control studies the association 
of BMI categories with VT risk was slightly attenuated by adjustment for factor VIII and 
activated protein C resistance [26]. In a case-control study Abdollahi reported that 
adjustment for levels of some coagulation and inflammation factors that are correlated with 
obesity and VT risk (factors VIII and IX, D-dimer, fibrinogen and C-reactive protein) did 
not attenuate the association of obesity (assessed as elevated BMI) with VT [5]. In contrast, 
the Reasons for Geographic and Racial Differences in Stroke cohort investigators reported, 
in a prospective study like that presented here, that CRP mediated 15% of the association of 
BMI (expressed as a continuous variable) with VT risk and that albumin, which was not 
studied here, mediated 41% of the risk [27]. That study included a larger representation of 
African-Americans, who have higher levels of inflammation markers than whites, the cohort 
had more obesity at baseline, and was enrolled later in time (2003–7) than the LITE cohorts. 
Taken together, findings suggest that hypercoagulability does not explain the association of 
obesity with thrombosis, and there is mixed information on whether inflammation plays a 
role, so further study is necessary.
Along with other work[5], findings here support a hypothesis that the physical impact of 
body size is more important in VT pathophysiology than the metabolic activity of adipose 
tissue in relation to hemostatic function[28]. Greater blood volume moving against gravity 
from the legs may also be important. Our prior report from the LITE study that persons with 
longer legs have higher risk of VT corroborates this hypothesis[29], as do the similar 
associations of fat-free mass and fat mass with VT seen here; this finding is also not 
surprising given the lack of mediation of obesity and VT risk by biomarkers related to 
adipose tissue that we observed. Obesity is also associated with venous insufficiency[30, 
31], thus obesity may cause impaired venous return, which can lead to chronic venous 
insufficiency and/or DVT. One cross-sectional study reported higher levels of the adipokines 
resistin, leptin and tumor necrosis factor-alpha (TNF-alpha) with venous insufficiency, 
independent of BMI[32]. We are not aware of studies of resistin or leptin and VT risk, while 
one prospective study suggested no association of TNF-alpha with VT risk[33]. Adipokines 
appear to mediate a prothrombotic state in obesity manifest as higher factor VII, 
plasminogen activator inhibitor-1 (PAI-1), fibrinogen and activation of platelets and tissue 
factor[34, 35]. Some of these factors, like fibrinogen and PAI-1, were not considered here 
since they were not risk factors for VT in the LITE study[36, 37]. Further study on 
adipokines and VT is needed to address these questions.
In this study severe obesity was more strongly related to PE than DVT, suggesting a 
hypothesis that physical factors might contribute to the likelihood of embolization in this 
group, making VT a more serious disease. We did not observe this for other body size 
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measures. A recent review, using the same method here to compare risks for DVT versus PE, 
suggested the opposite, that obesity status was more strongly associated with DVT than 
PE[18], but this was based on only two studies[38, 39]. In another report from two Danish 
cohorts the association of increasing BMI, and of a genetic variant for obesity (FTO 
rs9939609, thought to regulate appetite) was greater for DVT plus PE than for DVT alone 
[40], but the difference in the RR for PE versus DVT was <2.0 suggesting no greater 
absolute risk for PE with obesity. A limitation of most research in this area is shared by the 
current study; namely that in routine practice patients are not systematically evaluated for 
both DVT and PE upon presentation with one or the other disorder, and this may lead to 
misclassification of event type since the two manifestations are frequently asymptomatic. 
More work is needed to address this question.
This study has strengths and limitations. LITE is one of the few large prospective studies 
with measured risk factors that assessed incidence of VT, which eliminates the likelihood of 
reverse causality seen in retrospective studies and reduces some types of bias. However, 
misclassification of exposures is important to consider since baseline levels of risk factors 
could change over time, in particular levels of obesity and of some biomarkers such as D-
dimer that rise with age[41]. The large majority of older adults have stable, increasing or 
cycling weight over time[42]. Measurement error also introduces misclassification in every 
epidemiologic study since baseline risk factors are measured with error. These issues may 
have caused underestimation of risk associations and also may have reduced our ability to 
detect mediation. Baseline risk factors and laboratory measures in ARIC and CHS were 
performed with standardized methods so we expect that the impact of measurement error 
was minimized, although we could not control error from within-person variability. In 
addition, we did not measure every biomarker that might link obesity with VT risk, nor did 
we assess liver steatosis or adipokines, so an unmeasured mediator might be considered. 
Despite the above limitations, careful data collection, inclusion of whites and African-
Americans and a 12.6 year follow up with detailed ascertainment of VT events were 
strengths of the study.
Conclusion
In this study, several measures of body size were related to risk of VT, independent of 
biomarkers of hemostasis and inflammation that are related to obesity status. This suggests 
that in the setting of obesity, physical factors related to body size, are more likely to be 
causally related to VT than the biochemical effects of obesity evaluated in this study. 
Further, the seemingly differential associations of body size with PE compared to DVT in 
severe obesity suggest that VT might be a more serious disease in this situation. Since 
obesity is epidemic and increasing in both developed and developing nations[1], further 
study is required on the pathogenesis of VT in obese persons.
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Highlights
• Obesity is a leading risk factor for venous thrombosis (VT), with 
unknown mechanism
• Obesity drives a procoagulant, proinflammatory state
• We observed associations of most body size measures with VT risk
• Hemostasis and inflammation biomarkers did not substantially mediate 
associations
• Physical factors not biochemical effects, are more likely causal for VT 
in obesity
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Figure 1. 
Incidence of Venous Thrombosis by Body Size Measures. Incidence rates per 1000 person-
years are shown by sex-specific quartiles of each body size measure, other than BMI. BMI is 
shown by obesity categories. Calf circumference was only available in ARIC. Fat mass and 
fat-free mass were only available in CHS, and are shown in the inset.
Cutpoints for quartiles in men were: weight 73.9, 82.1, 91.2 kg; height 171, 175, 180 cm; 
waist circumference 92, 98, 105 cm; waist-hip ratio 0.93, 0.96, 1.00; calf circumference 36, 
38, 40 cm; fat mass 24.3, 29.9, 35.9 kg; fat-free mass 44.3, 48.1, 52.2 kg. Cutpoints for 
quartiles in women were: weight 60.1, 69.0, 80.3 kg; height 157, 161, 165 cm; waist 
circumference 83, 93, 104 cm; waist-hip ratio 0.84, 0.90, 0.96; calf circumference 34, 36, 39 
cm; fat mass 26.9, 33.3, 40.9 cm; fat-free mass 29.8, 32.5, 35.7 kg.
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Figure 2. 
Spearman Correlation Coefficients of Body Size Measures and Biomarkers. The darker 
shaded boxes indicate higher correlation coefficients.
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Table 1
Baseline Characteristics of Study Participants, LITE
Characteristic, mean (SD) or % Incident VT (n = 448) No VT (n = 20,466)
Age, years 63 (10) 59 (10)
Sex, female 55% 56%
Race, black 26% 24%
Diabetes 18% 13%
Weight, kg 81.3 (17.0) 76.9 (16.4)
Height, cm 168 (10) 168 (9)
BMI, kg/m2 28.8 (5.2) 27.4 (5.2)
Obesity 37% 25%
Waist circumference, cm 100 (14) 96 (14)
Elevated waist circumference 63% 51%
Hip circumference, cm 106 (11) 104 (10)
Waist-hip ratio 0.94 (0.08) 0.93 (0.08)
Calf circumference, cm* 38.5 (3.9) 37.4 (3.7)
Fat-free mass, kg† 41.5 (9.9) 39.6 (9.4)
Fat mass, kg† 35.3 (12.4) 32.8 (10.7)
*ARIC only
†CHS only
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Table 2
Relative Risk of Incident VT by Body Size or Biomarker Categories, Adjusted for Age, Race and Sex
Factor, SD
Relative Risk by Category of Each Factor
Compared to Lowest Category*
Relative Risk
per SD
Increment2 3 4
Body Size
Weight, 16.4 kg 1.3 (0.9–1.7) 1.5 (1.2–2.1) 2.6 (2.0–3.5) 1.4 (1.3–1.6)
Height, 9.5 cm 1.1 (0.9–1.5) 1.2 (0.9–1.6) 1.5 (1.1–1.9) 1.2 (1.1–1.4)
BMI, 5.2 kg/m2 1.4 (1.1–1.7) 2.2 (1.7–2.8) 3.0 (1.8–5.0) 1.3 (1.2–1.5)
Waist circumference, 13.7 cm 1.2 (0.9–1.6) 1.3 (1.0–1.8) 2.2 (1.7–2.8) 1.3 (1.2–1.5)
Elevated waist circumference 1.7 (1.4–2.1) - - -
Hip circumference, 10.4 cm 1.3 (1.0–1.8) 1.6 (1.2–2.1) 2.3 (1.8–3.1) 1.3 (1.2–1.4)
Waist-hip ratio, 0.08 1.3 (1.0–1.7) 1.5 (1.1–2.0) 1.7 (1.3–2.2) 1.2 (1.1–1.3)
Calf circumference, 3.7 cm† 1.4 (0.9–2.0) 2.0 (1.4–2.8) 2.5 (1.8–3.5) 1.4 (1.2–1.5)
Fat-free mass, 9.4 kg‡ 1.2 (0.8–2.0) 1.5 (0.9–2.3) 2.0 (1.3–3.1) 1.6 (1.2–2.0)
Fat Mass, 10.7 kg‡ 1.1 (0.7–1.7) 0.9 (0.5–1.4) 1.7 (1.1–2.7) 1.3 (1.1–1.5)
Hemostasis
Factor VIIc, 29% 1.2 (0.9–1.6) 1.0 (0.8–1.4) 1.4 (1.1–1.9) 1.1 (1.0–1.2)
Factor VIIIc, 39% 1.2 (0.9–1.6) 1.6 (1.2–2.2) 2.5 (1.8–3.3) 1.4 (1.3–1.5)
Factor XI, 37%§ 1.4 (1.0, 1.9) 1.5 (1.1, 2.1) 2.0 (1.4–2.8) 1.2 (1.0–1.4)
von Willebrand factor, 1.5%†║ 1.6 (1.0–2.4) 1.3 (0.8–2.0) 3.4 (2.4–5.0) 1.7 (1.5–1.9)
Fibrinogen, 66 mg/dL 1.0 (0.8–1.4) 1.2 (0.9–1.5) 1.0 (0.8–1.3) 1.0 (0.9–1.1)
aPTT, 3.0 sec † 0.7 (0.5–1.0) 0.4 (0.2–0.5) 0.4 (0.3–0.6) 0.6 (0.6–0.7)
Protein C, 0.62 ug/ml † 1.2 (0.9–1.8) 1.3 (0.9–1.9) 1.1 (0.7–1.5) 1.0 (0.9–1.1)
D-dimer, 2.3 ug/ml §║ 1.1 (0.8, 1.6) 1.9 (1.4, 2.7) 2.1 (1.5, 3.0) 1.3 (1.2, 1.5)
Inflammation
Leukocyte count, 1.3 ×109/L║ 0.8 (0.6–1.1) 0.9 (0.7–1.2) 0.9 (0.7–1.2) 1.0 (0.9–1.1)
C-reactive protein, 2.8 mg/L‡║ 1.1 (0.7–1.6) 0.9 (0.6–1.4) 0.9 (0.6–2.1) 1.1 (1.0–1.3)
Interkeukin-6, 1.9 pg/ml‡║ 0.9 (0.5–1.5) 1.1 (0.6–1.7) 1.1 (0.6–1.7) 1.0 (0.8–1.2)
*Categories are quartiles except BMI was overweight (2), obese (3) or severely obese (4) compared to normal, and elevated waist circumference 
(2).
†ARIC participants only
‡CHS participants only
§Nested case-control study only
║
For skewed variables the HR per SD increment of each factor was calculated as the HR per SD of the log transformed distribution and the SD 
was transformed back to the original units for presentation.
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